(Q37812060)

23 August 2017

Medical and surgical treatment options for polycystic liver disease (English)

1 reference

23 August 2017

Joost P H Drenth

1

1 reference

23 August 2017

Melissa Chrispijn

2

1 reference

23 August 2017

David M Nagorney

3

1 reference

23 August 2017

Patrick S Kamath

4

1 reference

23 August 2017

Vicente E Torres

5

1 reference

23 August 2017

language of work or name

English

0 references

publication date

1 December 2010

1 reference

23 August 2017

1 reference

23 August 2017

52

1 reference

23 August 2017

2223-2230

1 reference

23 August 2017

6

1 reference

Hepatic cysts: treatment with alcohol.

23 August 2017

1 reference

Surgical management of polycystic liver disease

21 January 2018

1 reference

Autosomal dominant polycystic kidney disease

21 January 2018

1 reference

7 January 2021

Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial.

1 reference

7 January 2021

Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease

1 reference

7 January 2021

Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide

1 reference

7 January 2021

Autosomal Dominant Polycystic Kidney Disease Types 1 and 2: Assessment of US Sensitivity for Diagnosis

1 reference

7 January 2021

Magnetic resonance imaging evaluation of hepatic cysts in early autosomal-dominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort

1 reference

7 January 2021

Extensive mutational analysis of PRKCSH and SEC63 broadens the spectrum of polycystic liver disease

1 reference

7 January 2021

Secondary and tertiary structure modeling reveals effects of novel mutations in polycystic liver disease genes PRKCSH and SEC63.

1 reference

7 January 2021

Congenital disorders of glycosylation in hepatology: the example of polycystic liver disease

1 reference

7 January 2021

The cholangiopathies: disorders of biliary epithelia

1 reference

7 January 2021

Regulation and deregulation of cholangiocyte proliferation

1 reference

7 January 2021

Sirolimus reduces polycystic liver volume in ADPKD patients

1 reference

7 January 2021

Regulation of cholangiocyte proliferation

1 reference

7 January 2021

The polycystic kidney disease 1 gene product mediates protein kinase C alpha-dependent and c-Jun N-terminal kinase-dependent activation of the transcription factor AP-1

1 reference

7 January 2021

Cyclic AMP activates B-Raf and ERK in cyst epithelial cells from autosomal-dominant polycystic kidneys

1 reference

7 January 2021

Polycystic liver: clinical characteristics of patients with isolated polycystic liver disease compared with patients with polycystic liver and autosomal dominant polycystic kidney disease.

1 reference

7 January 2021

New advances in evaluation and management of patients with polycystic liver disease

1 reference

7 January 2021

Polycystic liver disease: experience at a teaching hospital

1 reference

7 January 2021

Carbohydrate antigen 19-9 is extremely elevated in polycystic liver disease

1 reference

7 January 2021

Elevation of CA-125 level is due to abdominal distension in liver transplantation candidates

1 reference

7 January 2021

Determination of tumor marker levels in cystic fluid of benign liver cysts

1 reference

7 January 2021

A 22-year-old man with a liver mass and markedly elevated serum alpha fetoprotein

1 reference

7 January 2021

Percutaneous aspiration of hepatic cysts does not provide definitive therapy

1 reference

7 January 2021

Aspiration-sclerotherapy results in effective control of liver volume in patients with liver cysts

1 reference

7 January 2021

Treatment of symptomatic hepatic cysts by percutaneous instillation of minocycline hydrochloride

1 reference

7 January 2021

Alcohol sclerotherapy of hepatic cysts: its effect in relation to ethanol concentration

1 reference

7 January 2021

Laparoscopic fenestration of liver cysts in polycystic liver disease results in a median volume reduction of 12.5%.

1 reference

7 January 2021

Tailoring the management of nonparasitic liver cysts.

1 reference

7 January 2021

Surgical treatment of non-parasitic hepatic cysts: report of 12 cases

1 reference

7 January 2021

Partial resection and fenestration in the treatment of polycystic liver disease

1 reference

7 January 2021

The value of residual liver volume as a predictor of hepatic dysfunction and infection after major liver resection

1 reference

7 January 2021

Secretin promotes osmotic water transport in rat cholangiocytes by increasing aquaporin-1 water channels in plasma membrane. Evidence for a secretin-induced vesicular translocation of aquaporin-1.

1 reference

7 January 2021

Regulated vesicle trafficking of membrane transporters in hepatic epithelia

1 reference

7 January 2021

Somatostatin receptors

1 reference

7 January 2021

Somatostatin-14 and somatostatin-28 pretreatment down-regulate somatostatin-14 receptors and have biphasic effects on forskolin-stimulated cyclic adenosine, 3',5'-monophosphate synthesis and adrenocorticotropin secretion in mouse anterior pituitary

1 reference

7 January 2021

Occurrence of an Inhibitory Guanine Nucleotide-Binding Regulatory Component of the Adenylate Cyclase System in cyc- Variants of S49 Lymphoma Cells

1 reference

7 January 2021

Human cholangiocarcinomas express somatostatin receptors and respond to somatostatin with growth inhibition

1 reference

7 January 2021

Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3',5'-cyclic monophosphate.

1 reference

7 January 2021

Somatostatin analogues reduce liver volume in polycystic liver disease

1 reference

7 January 2021

Effect of octreotide on polycystic liver volume

1 reference

7 January 2021

Therapeutic approaches in autosomal dominant polycystic kidney disease (ADPKD): is there light at the end of the tunnel?

1 reference

7 January 2021

Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease

1 reference

7 January 2021

Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD).

1 reference

7 January 2021

Sirolimus and kidney growth in autosomal dominant polycystic kidney disease

1 reference

7 January 2021

Everolimus in patients with autosomal dominant polycystic kidney disease.

1 reference

7 January 2021

Identifiers

DOI

10.1002/HEP.24036

1 reference

23 August 2017

1 reference